These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19385721)

  • 1. Treatment of HIV infection with raltegravir.
    Chirch LM; Morrison S; Steigbigel RT
    Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir as antiretroviral therapy in HIV/AIDS.
    Sharma M; Walmsley SL
    Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: an integrase inhibitor for HIV-1.
    Evering TH; Markowitz M
    Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
    Croxtall JD; Keam SJ
    Drugs; 2009 May; 69(8):1059-75. PubMed ID: 19496631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: in treatment-naive patients with HIV-1 infection.
    Croxtall JD; Scott LJ
    Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics and interactions of raltegravir].
    Placeres Alsina MM; Tuset Creus M; Miró JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():23-8. PubMed ID: 19572422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir: molecular basis of its mechanism of action.
    Mouscadet JF; Tchertanov L
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):5-16. PubMed ID: 19959411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
    Calcagno A; D'Avolio A; Bonora S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.
    Squires KE; Bekker LG; Eron JJ; Cheng B; Rockstroh JK; Marquez F; Kumar P; Thompson M; Campo RE; Mounzer K; Strohmaier KM; Lu C; Rodgers A; Jackson BE; Wenning LA; Robertson M; Nguyen BY; Sklar P;
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):859-70. PubMed ID: 23351187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.